BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 9387 hits with Last Name = 'tanner' and Initial = 'h'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151989
PNG
(US8987457, 183)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC2CCOCC2)cc1F |r,wU:3.13,1.0,5.5,7.8,(-.67,.38,;-2,-.38,;-2,-1.93,;-3.33,-2.69,;-4.67,-1.93,;-4.67,-.38,;-6,.38,;-3.33,.38,;-3.33,1.93,;-4.67,2.69,;-4.67,4.23,;-6,5,;-7.34,5.78,;-3.33,-4.23,;-4.67,-5,;-4.67,-6.54,;-3.33,-7.31,;-2,-6.54,;-2,-5,;-.67,-4.23,;.67,-5,;.67,-6.54,;2,-4.23,;3.33,-5,;4.67,-4.23,;4.67,-2.69,;6,-1.92,;3.33,-1.93,;2,-2.69,;3.33,-.38,;2,.38,;.67,-.38,;2,1.93,;3.33,2.69,;3.33,4.23,;4.67,5,;6,4.23,;7.34,5,;7.34,6.54,;6,7.31,;4.67,6.54,;4.67,1.93,;4.67,.38,;6,-.38,)|
Show InChI InChI=1S/C32H34F3N5O4/c1-18-13-19(14-26(37)31(18)43-10-2-8-36)22-5-9-38-17-28(22)40-32(41)27-4-3-23(33)30(39-27)29-24(34)15-21(16-25(29)35)44-20-6-11-42-12-7-20/h3-5,9,15-20,26,31H,2,6-7,10-14,37H2,1H3,(H,40,41)/t18-,19+,26+,31-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0100n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151905
PNG
(US8987457, 99)
Show SMILES CO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1CCOCC1 |r,wU:6.10,8.9,3.3,2.1,(-2,2.69,;-3.33,1.93,;-3.33,.38,;-2,-.38,;-.67,.39,;-2,-1.92,;-3.33,-2.69,;-4.67,-1.92,;-4.67,-.38,;-6,.39,;-3.33,-4.23,;-4.67,-5,;-4.67,-6.54,;-3.33,-7.31,;-2,-6.54,;-2,-5,;-.67,-4.23,;.67,-5,;.67,-6.54,;2,-4.23,;3.33,-5,;4.67,-4.23,;4.67,-2.69,;6,-1.92,;3.33,-1.93,;2,-2.69,;3.33,-.38,;2,.38,;.67,-.38,;2,1.93,;3.33,2.69,;4.67,1.93,;4.67,.38,;6,-.38,;3.33,4.23,;4.67,5,;4.67,6.54,;3.33,7.31,;2,6.54,;2,5,)|
Show InChI InChI=1S/C30H33F3N4O3/c1-16-11-19(14-24(34)29(16)39-2)20-5-8-35-15-26(20)37-30(38)25-4-3-21(31)28(36-25)27-22(32)12-18(13-23(27)33)17-6-9-40-10-7-17/h3-5,8,12-13,15-17,19,24,29H,6-7,9-11,14,34H2,1-2H3,(H,37,38)/t16-,19+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0100n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151889
PNG
(US8987457, 83)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:3.13,5.5,1.0,7.8,(-.67,1.16,;-2,.39,;-2,-1.15,;-3.33,-1.93,;-4.67,-1.15,;-4.67,.39,;-6,1.16,;-3.33,1.15,;-3.33,2.69,;-2,3.47,;-2,5,;-.67,5.78,;.67,6.54,;-3.33,-3.47,;-4.67,-4.23,;-4.67,-5.78,;-3.33,-6.54,;-2,-5.78,;-2,-4.23,;-.67,-3.47,;.67,-4.23,;.67,-5.78,;2,-3.47,;3.33,-4.23,;4.67,-3.47,;4.67,-1.93,;6,-1.15,;3.33,-1.15,;2,-1.93,;3.33,.38,;2,1.15,;.67,.38,;2,2.69,;3.33,3.47,;3.33,5,;4.67,2.69,;4.67,1.15,;6,.38,)|
Show InChI InChI=1S/C28H28F3N5O2/c1-15-10-20(30)25(21(31)11-15)26-19(29)4-5-23(35-26)28(37)36-24-14-34-8-6-18(24)17-12-16(2)27(22(33)13-17)38-9-3-7-32/h4-6,8,10-11,14,16-17,22,27H,3,9,12-13,33H2,1-2H3,(H,36,37)/t16-,17+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0100n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151870
PNG
(US8987457, 64)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1nc(sc1N)-c1c(F)cccc1F |r|
Show InChI InChI=1S/C25H26F2N6O2S/c1-13-10-14(11-18(29)22(13)35-9-3-7-28)15-6-8-31-12-19(15)32-24(34)21-23(30)36-25(33-21)20-16(26)4-2-5-17(20)27/h2,4-6,8,12-14,18,22H,3,9-11,29-30H2,1H3,(H,32,34)/t13-,14+,18+,22-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0100n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151959
PNG
(US8987457, 153)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(F)CCOCC1 |r,wU:3.13,1.0,5.5,7.8,(,.38,;-1.33,-.38,;-1.33,-1.93,;-2.67,-2.69,;-4,-1.93,;-4,-.38,;-5.33,.38,;-2.67,.38,;-2.67,1.93,;-4,2.69,;-4,4.23,;-5.33,5,;-6.67,5.78,;-2.67,-4.23,;-4,-5,;-4,-6.54,;-2.67,-7.31,;-1.33,-6.54,;-1.33,-5,;,-4.23,;1.33,-5,;1.33,-6.54,;2.67,-4.23,;4,-5,;5.33,-4.23,;5.33,-2.69,;6.67,-1.92,;4,-1.93,;2.67,-2.69,;4,-.38,;2.67,.38,;1.33,-.38,;2.67,1.93,;4,2.69,;5.33,1.93,;5.33,.38,;6.67,-.38,;4,4.23,;5.33,3.47,;5.33,5,;5.33,6.54,;4,7.31,;2.67,6.54,;2.67,5,)|
Show InChI InChI=1S/C32H33F4N5O3/c1-18-13-19(14-25(38)30(18)44-10-2-8-37)21-5-9-39-17-27(21)41-31(42)26-4-3-22(33)29(40-26)28-23(34)15-20(16-24(28)35)32(36)6-11-43-12-7-32/h3-5,9,15-19,25,30H,2,6-7,10-14,38H2,1H3,(H,41,42)/t18-,19+,25+,30-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0100n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase B-raf [V600E]


(Homo sapiens (Human))
BDBM87369
PNG
(US10245267, Example 704 | US10709712, Example 704 ...)
Show SMILES CCNc1nc(cc(n1)-c1cc(NC(=O)c2cccc(c2)S(C)(=O)=O)ccc1C)N1CCOCC1
Show InChI InChI=1S/C25H29N5O4S/c1-4-26-25-28-22(16-23(29-25)30-10-12-34-13-11-30)21-15-19(9-8-17(21)2)27-24(31)18-6-5-7-20(14-18)35(3,32)33/h5-9,14-16H,4,10-13H2,1-3H3,(H,27,31)(H,26,28,29)
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



NOVARTIS AG

US Patent


Assay Description
C-Raf TR refers to a truncated C-Raf protein, a Δ1-324 deletion mutant.C-Raf FL refers to the full-length C-Raf protein.Full length MEK1 with an...


US Patent US10709712 (2020)


BindingDB Entry DOI: 10.7270/Q2280BP3
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151879
PNG
(US8987457, 73)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:3.15,5.5,1.0,7.8,(-.67,.87,;-2,.1,;-2,-1.44,;-3.33,-2.21,;-4.67,-1.44,;-4.67,.1,;-6,.87,;-3.33,.87,;-3.33,2.41,;-2,3.18,;-2,4.72,;-.67,5.49,;.67,6.26,;-1.44,6.83,;.1,4.16,;-3.33,-3.75,;-4.67,-4.52,;-4.67,-6.06,;-3.33,-6.83,;-2,-6.06,;-2,-4.52,;-.67,-3.75,;.67,-4.52,;.67,-6.06,;2,-3.75,;3.33,-4.52,;4.67,-3.75,;4.67,-2.21,;6,-1.44,;3.33,-1.44,;2,-2.21,;3.33,.1,;2,.87,;.67,.1,;2,2.41,;3.33,3.18,;3.33,4.72,;4.67,2.41,;4.67,.87,;6,.1,)|
Show InChI InChI=1S/C28H31F3N4O4S/c1-15-10-20(30)25(21(31)11-15)26-19(29)4-5-23(34-26)28(36)35-24-14-33-7-6-18(24)17-12-16(2)27(22(32)13-17)39-8-9-40(3,37)38/h4-7,10-11,14,16-17,22,27H,8-9,12-13,32H2,1-3H3,(H,35,36)/t16-,17+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase B-raf [V600E]


(Homo sapiens (Human))
BDBM87369
PNG
(US10245267, Example 704 | US10709712, Example 704 ...)
Show SMILES CCNc1nc(cc(n1)-c1cc(NC(=O)c2cccc(c2)S(C)(=O)=O)ccc1C)N1CCOCC1
Show InChI InChI=1S/C25H29N5O4S/c1-4-26-25-28-22(16-23(29-25)30-10-12-34-13-11-30)21-15-19(9-8-17(21)2)27-24(31)18-6-5-7-20(14-18)35(3,32)33/h5-9,14-16H,4,10-13H2,1-3H3,(H,27,31)(H,26,28,29)
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/a7.525



NOVARTIS AG

US Patent


Assay Description
Raf and biotinylated Mek, kinase dead, were combined at 2x final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...


US Patent US9694016 (2017)


BindingDB Entry DOI: 10.7270/Q2MC8X6W
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151972
PNG
(US8987457, 166)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1nc(c(F)cc1N)-c1c(F)cccc1F |r,wU:3.13,1.0,5.5,7.8,(-.67,1.15,;-2,.38,;-2,-1.15,;-3.33,-1.93,;-4.67,-1.15,;-4.67,.38,;-6,1.15,;-3.33,1.15,;-3.33,2.69,;-2,3.47,;-2,5,;-.67,5.78,;.67,6.54,;-3.33,-3.47,;-4.67,-4.23,;-4.67,-5.78,;-3.33,-6.54,;-2,-5.78,;-2,-4.23,;-.67,-3.47,;.67,-4.23,;.67,-5.78,;2,-3.47,;2,-1.93,;3.33,-1.15,;4.67,-1.93,;6,-1.15,;4.67,-3.47,;3.33,-4.23,;3.33,-5.77,;3.33,.38,;2,1.15,;.67,.38,;2,2.69,;3.33,3.47,;4.67,2.69,;4.67,1.15,;6,.38,)|
Show InChI InChI=1S/C27H27F3N6O2/c1-14-10-15(11-21(33)26(14)38-9-3-7-31)16-6-8-34-13-22(16)35-27(37)25-20(32)12-19(30)24(36-25)23-17(28)4-2-5-18(23)29/h2,4-6,8,12-15,21,26H,3,9-11,32-33H2,1H3,(H,35,37)/t14-,15+,21+,26-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151977
PNG
(US8987457, 171)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC2CCOCC2)cc1F |r,wU:3.14,1.0,5.5,7.8,(-1.33,.38,;-2.67,-.38,;-2.67,-1.93,;-4,-2.69,;-5.33,-1.93,;-5.33,-.38,;-6.67,.38,;-4,.38,;-4,1.93,;-5.25,2.83,;-4.77,4.29,;-3.23,4.29,;-2.76,2.83,;-4,-4.23,;-5.33,-5,;-5.33,-6.54,;-4,-7.31,;-2.67,-6.54,;-2.67,-5,;-1.33,-4.23,;,-5,;,-6.54,;1.33,-4.23,;2.67,-5,;4,-4.23,;4,-2.69,;5.33,-1.92,;2.67,-1.93,;1.33,-2.69,;2.67,-.38,;1.33,.38,;,-.38,;1.33,1.93,;2.67,2.69,;2.67,4.23,;4,5,;5.33,4.24,;6.67,5,;6.67,6.54,;5.33,7.31,;4,6.54,;4,1.93,;4,.38,;5.33,-.38,)|
Show InChI InChI=1S/C31H32F3N7O3/c1-17-12-18(13-25(35)30(17)41-9-8-37-40-41)21-4-7-36-16-27(21)39-31(42)26-3-2-22(32)29(38-26)28-23(33)14-20(15-24(28)34)44-19-5-10-43-11-6-19/h2-4,7-9,14-19,25,30H,5-6,10-13,35H2,1H3,(H,39,42)/t17-,18+,25+,30-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151980
PNG
(US8987457, 174)
Show SMILES COC(=O)N[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1nc(c(F)cc1N)-c1c(F)cccc1F |r,wU:6.6,11.12,5.4,(.67,4.23,;-.67,3.47,;-2,4.23,;-2,5.78,;-3.33,3.47,;-3.33,1.93,;-2,1.15,;-.67,1.93,;-2,-.38,;-3.33,-1.15,;-4.67,-.38,;-4.67,1.15,;-6,1.93,;-3.33,-2.69,;-4.67,-3.47,;-4.67,-5,;-3.33,-5.78,;-2,-5,;-2,-3.47,;-.67,-2.69,;.67,-3.47,;.67,-5,;2,-2.69,;2,-1.15,;3.33,-.38,;4.67,-1.15,;6,-.38,;4.67,-2.69,;3.33,-3.46,;3.33,-5,;3.33,1.15,;2,1.93,;.67,1.15,;2,3.47,;3.33,4.23,;4.67,3.47,;4.67,1.93,;6,1.15,)|
Show InChI InChI=1S/C25H26F3N7O3/c1-12-10-35(11-17(30)21(12)34-25(37)38-2)19-6-7-31-9-18(19)32-24(36)23-16(29)8-15(28)22(33-23)20-13(26)4-3-5-14(20)27/h3-9,12,17,21H,10-11,29-30H2,1-2H3,(H,32,36)(H,34,37)/t12-,17+,21-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151982
PNG
(US8987457, 176)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1nc(c(F)cc1N)-c1c(F)cccc1F |r,wU:3.14,1.0,5.5,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;2,-1.18,;3.33,-.41,;4.67,-1.18,;6,-.41,;4.67,-2.72,;3.33,-3.49,;3.33,-5.03,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C26H25F3N8O/c1-13-9-14(10-20(31)25(13)37-8-7-33-36-37)15-5-6-32-12-21(15)34-26(38)24-19(30)11-18(29)23(35-24)22-16(27)3-2-4-17(22)28/h2-8,11-14,20,25H,9-10,30-31H2,1H3,(H,34,38)/t13-,14+,20+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151990
PNG
(US8987457, 184)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCC#N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCC1 |r,wU:3.13,1.0,5.5,7.8,(,.84,;-1.33,.07,;-1.33,-1.47,;-2.67,-2.24,;-4,-1.47,;-4,.07,;-5.33,.84,;-2.67,.84,;-2.67,2.38,;-4,3.15,;-4,4.69,;-5.33,5.46,;-6.67,6.23,;-2.67,-3.78,;-4,-4.55,;-4,-6.09,;-2.67,-6.86,;-1.33,-6.09,;-1.33,-4.55,;,-3.78,;1.33,-4.55,;1.33,-6.09,;2.67,-3.78,;4,-4.55,;5.33,-3.78,;5.33,-2.24,;6.67,-1.47,;4,-1.47,;2.67,-2.24,;4,.07,;2.67,.84,;1.33,.07,;2.67,2.38,;4,3.15,;5.33,2.38,;5.33,.84,;6.67,.07,;4,4.69,;5.33,3.92,;5.09,5.77,;4,6.86,;2.91,5.77,)|
Show InChI InChI=1S/C31H32F3N5O3/c1-17-12-18(13-24(36)29(17)42-11-3-9-35)20-6-10-37-16-26(20)39-30(40)25-5-4-21(32)28(38-25)27-22(33)14-19(15-23(27)34)31(41)7-2-8-31/h4-6,10,14-18,24,29,41H,2-3,7-8,11-13,36H2,1H3,(H,39,40)/t17-,18+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151901
PNG
(US8987457, 95)
Show SMILES CO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C(C)C |r,wU:6.10,8.9,3.3,2.1,(-2,3.85,;-3.33,3.08,;-3.33,1.54,;-2,.77,;-.67,1.54,;-2,-.77,;-3.33,-1.54,;-4.67,-.77,;-4.67,.77,;-6,1.54,;-3.33,-3.08,;-4.67,-3.85,;-4.67,-5.39,;-3.33,-6.16,;-2,-5.39,;-2,-3.85,;-.67,-3.08,;.67,-3.85,;.67,-5.39,;2,-3.08,;3.33,-3.85,;4.67,-3.08,;4.67,-1.54,;6,-.77,;3.33,-.77,;2,-1.54,;3.33,.77,;2,1.54,;.67,.77,;2,3.08,;3.33,3.85,;4.67,3.08,;4.67,1.54,;6,.77,;3.33,5.39,;4.67,6.16,;2,6.16,)|
Show InChI InChI=1S/C28H31F3N4O2/c1-14(2)16-10-20(30)25(21(31)11-16)26-19(29)5-6-23(34-26)28(36)35-24-13-33-8-7-18(24)17-9-15(3)27(37-4)22(32)12-17/h5-8,10-11,13-15,17,22,27H,9,12,32H2,1-4H3,(H,35,36)/t15-,17+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151907
PNG
(US8987457, 101)
Show SMILES CO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC(C)C)cc1F |r,wU:6.10,8.9,3.3,2.1,(-2,3.08,;-3.33,2.31,;-3.33,.77,;-2,,;-.67,.77,;-2,-1.54,;-3.33,-2.31,;-4.67,-1.54,;-4.67,,;-6,.77,;-3.33,-3.85,;-4.67,-4.62,;-4.67,-6.16,;-3.33,-6.93,;-2,-6.16,;-2,-4.62,;-.67,-3.85,;.67,-4.62,;.67,-6.16,;2,-3.85,;3.33,-4.62,;4.67,-3.85,;4.67,-2.31,;6,-1.54,;3.33,-1.54,;2,-2.31,;3.33,,;2,.77,;.67,,;2,2.31,;3.33,3.08,;3.33,4.62,;4.67,5.39,;4.67,6.93,;6,4.62,;4.67,2.31,;4.67,.77,;6,,)|
Show InChI InChI=1S/C28H31F3N4O3/c1-14(2)38-17-11-20(30)25(21(31)12-17)26-19(29)5-6-23(34-26)28(36)35-24-13-33-8-7-18(24)16-9-15(3)27(37-4)22(32)10-16/h5-8,11-16,22,27H,9-10,32H2,1-4H3,(H,35,36)/t15-,16+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151924
PNG
(US8987457, 118)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCOCC1 |r,wU:3.15,5.5,1.0,7.8,(.1,.39,;-1.23,-.38,;-1.23,-1.92,;-2.56,-2.69,;-3.9,-1.92,;-3.9,-.38,;-5.23,.39,;-2.56,.38,;-2.56,1.93,;-3.9,2.69,;-3.9,4.23,;-5.23,5,;-5.23,6.54,;-6.77,5,;-6,3.67,;-2.56,-4.23,;-3.9,-5,;-3.9,-6.54,;-2.56,-7.31,;-1.23,-6.54,;-1.23,-5,;.1,-4.23,;1.44,-5,;1.44,-6.54,;2.77,-4.23,;4.1,-5,;5.44,-4.23,;5.44,-2.69,;6.77,-1.92,;4.1,-1.93,;2.77,-2.69,;4.1,-.38,;2.77,.38,;1.44,-.38,;2.77,1.93,;4.1,2.69,;5.44,1.93,;5.44,.38,;6.77,-.38,;4.1,4.23,;5.44,3.47,;5.44,5,;5.44,6.54,;4.1,7.31,;2.77,6.54,;2.77,5,)|
Show InChI InChI=1S/C32H37F3N4O6S/c1-18-13-19(14-25(36)30(18)45-11-12-46(2,42)43)21-5-8-37-17-27(21)39-31(40)26-4-3-22(33)29(38-26)28-23(34)15-20(16-24(28)35)32(41)6-9-44-10-7-32/h3-5,8,15-19,25,30,41H,6-7,9-14,36H2,1-2H3,(H,39,40)/t18-,19+,25+,30-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151941
PNG
(US8987457, 135)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1nc(sc1N)-c1c(F)cccc1F |r|
Show InChI InChI=1S/C25H29F2N5O4S2/c1-13-10-14(11-18(28)22(13)36-8-9-38(2,34)35)15-6-7-30-12-19(15)31-24(33)21-23(29)37-25(32-21)20-16(26)4-3-5-17(20)27/h3-7,12-14,18,22H,8-11,28-29H2,1-2H3,(H,31,33)/t13-,14+,18+,22-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151943
PNG
(US8987457, 137)
Show SMILES CO[C@@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC2CCOCC2)cc1F |r,wU:6.10,3.3,8.9,wD:2.1,(-5.33,2.69,;-4,1.93,;-4,.38,;-2.67,-.38,;-1.33,.38,;-2.67,-1.93,;-4,-2.69,;-5.33,-1.93,;-5.33,-.38,;-6.67,.38,;-4,-4.23,;-5.33,-5,;-5.33,-6.54,;-4,-7.31,;-2.67,-6.54,;-2.67,-5,;-1.33,-4.23,;,-5,;,-6.54,;1.33,-4.23,;2.67,-5,;4,-4.23,;4,-2.69,;5.33,-1.92,;2.67,-1.93,;1.33,-2.69,;2.67,-.38,;1.33,.38,;,-.38,;1.33,1.93,;2.67,2.69,;2.67,4.23,;4,5,;5.33,4.24,;6.67,5,;6.67,6.54,;5.33,7.31,;4,6.54,;4,1.93,;4,.38,;5.33,-.38,)|
Show InChI InChI=1S/C30H33F3N4O4/c1-16-11-17(12-24(34)29(16)39-2)20-5-8-35-15-26(20)37-30(38)25-4-3-21(31)28(36-25)27-22(32)13-19(14-23(27)33)41-18-6-9-40-10-7-18/h3-5,8,13-18,24,29H,6-7,9-12,34H2,1-2H3,(H,37,38)/t16-,17+,24+,29+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151945
PNG
(US8987457, 139)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCC1 |r,wU:3.15,1.0,5.5,wD:7.8,(-.2,.84,;-1.53,.07,;-1.53,-1.47,;-2.87,-2.24,;-4.2,-1.47,;-4.2,.07,;-5.53,.84,;-2.87,.84,;-2.87,2.38,;-4.2,3.15,;-3.8,4.63,;-5.14,5.4,;-6.47,4.63,;-5.91,6.74,;-4.37,6.74,;-2.87,-3.78,;-4.2,-4.55,;-4.2,-6.09,;-2.87,-6.86,;-1.53,-6.09,;-1.53,-4.55,;-.2,-3.78,;1.13,-4.55,;1.13,-6.09,;2.47,-3.78,;3.8,-4.55,;5.14,-3.78,;5.14,-2.24,;6.47,-1.47,;3.8,-1.47,;2.47,-2.24,;3.8,.07,;2.47,.84,;1.13,.07,;2.47,2.38,;3.8,3.15,;5.14,2.38,;5.14,.84,;6.47,.07,;3.8,4.69,;5.14,3.92,;4.89,5.78,;3.8,6.86,;2.71,5.78,)|
Show InChI InChI=1S/C31H35F3N4O5S/c1-17-12-18(13-24(35)29(17)43-10-11-44(2,41)42)20-6-9-36-16-26(20)38-30(39)25-5-4-21(32)28(37-25)27-22(33)14-19(15-23(27)34)31(40)7-3-8-31/h4-6,9,14-18,24,29,40H,3,7-8,10-13,35H2,1-2H3,(H,38,39)/t17-,18+,24+,29+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151946
PNG
(US8987457, 140)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC2CCOCC2)cc1F |r,wU:3.15,1.0,5.5,wD:7.8,(-.87,.38,;-2.2,-.38,;-2.2,-1.93,;-3.53,-2.69,;-4.87,-1.93,;-4.87,-.38,;-6.2,.38,;-3.53,.38,;-3.53,1.93,;-4.87,2.69,;-4.47,4.18,;-5.8,4.95,;-7.14,4.18,;-6.57,6.29,;-5.03,6.29,;-3.53,-4.23,;-4.87,-5,;-4.87,-6.54,;-3.53,-7.31,;-2.2,-6.54,;-2.2,-5,;-.87,-4.23,;.47,-5,;.47,-6.54,;1.8,-4.23,;3.13,-5,;4.47,-4.23,;4.47,-2.69,;5.8,-1.92,;3.13,-1.93,;1.8,-2.69,;3.13,-.38,;1.8,.38,;.47,-.38,;1.8,1.93,;3.13,2.69,;3.13,4.23,;4.47,5,;5.8,4.24,;7.14,5,;7.14,6.54,;5.8,7.31,;4.47,6.54,;4.47,1.93,;4.47,.38,;5.8,-.38,)|
Show InChI InChI=1S/C32H37F3N4O6S/c1-18-13-19(14-26(36)31(18)44-11-12-46(2,41)42)22-5-8-37-17-28(22)39-32(40)27-4-3-23(33)30(38-27)29-24(34)15-21(16-25(29)35)45-20-6-9-43-10-7-20/h3-5,8,15-20,26,31H,6-7,9-14,36H2,1-2H3,(H,39,40)/t18-,19+,26+,31+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151947
PNG
(US8987457, 141)
Show SMILES CC(C)Oc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1[C@@H]1C[C@H](C)[C@H](OCCS(C)(=O)=O)[C@H](N)C1 |r,wU:28.30,30.33,40.43,32.35,(6,6.93,;6,5.39,;7.34,4.62,;4.67,4.62,;4.67,3.08,;3.33,2.31,;3.33,.77,;2,,;4.67,,;6,.77,;7.34,,;6,2.31,;4.67,-1.54,;3.33,-2.31,;3.33,-3.85,;4.67,-4.62,;6,-3.85,;6,-2.31,;7.34,-1.54,;2,-4.62,;2,-6.16,;.67,-3.85,;-.67,-4.62,;-.67,-6.16,;-2,-6.93,;-3.33,-6.16,;-3.33,-4.62,;-2,-3.85,;-2,-2.31,;-.67,-1.54,;-.67,,;.67,.77,;-2,.77,;-2,2.31,;-3.33,3.08,;-4.67,2.31,;-6,3.08,;-6.77,1.75,;-7.34,3.85,;-5.23,4.41,;-3.33,,;-4.67,.77,;-3.33,-1.54,)|
Show InChI InChI=1S/C30H35F3N4O5S/c1-16(2)42-19-13-22(32)27(23(33)14-19)28-21(31)5-6-25(36-28)30(38)37-26-15-35-8-7-20(26)18-11-17(3)29(24(34)12-18)41-9-10-43(4,39)40/h5-8,13-18,24,29H,9-12,34H2,1-4H3,(H,37,38)/t17-,18+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151948
PNG
(US8987457, 142)
Show SMILES CO[C@@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC(C)C)cc1F |r,wU:6.10,3.3,8.9,wD:2.1,(-2,3.08,;-3.33,2.31,;-3.33,.77,;-2,,;-.67,.77,;-2,-1.54,;-3.33,-2.31,;-4.67,-1.54,;-4.67,,;-6,.77,;-3.33,-3.85,;-4.67,-4.62,;-4.67,-6.16,;-3.33,-6.93,;-2,-6.16,;-2,-4.62,;-.67,-3.85,;.67,-4.62,;.67,-6.16,;2,-3.85,;3.33,-4.62,;4.67,-3.85,;4.67,-2.31,;6,-1.54,;3.33,-1.54,;2,-2.31,;3.33,,;2,.77,;.67,,;2,2.31,;3.33,3.08,;3.33,4.62,;4.67,5.39,;4.67,6.93,;6,4.62,;4.67,2.31,;4.67,.77,;6,,)|
Show InChI InChI=1S/C28H31F3N4O3/c1-14(2)38-17-11-20(30)25(21(31)12-17)26-19(29)5-6-23(34-26)28(36)35-24-13-33-8-7-18(24)16-9-15(3)27(37-4)22(32)10-16/h5-8,11-16,22,27H,9-10,32H2,1-4H3,(H,35,36)/t15-,16+,22+,27+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151950
PNG
(US8987457, 144)
Show SMILES COc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1[C@@H]1C[C@H](C)[C@H](OCCS(C)(=O)=O)[C@H](N)C1 |r,wU:26.28,28.31,38.41,30.33,(5.33,5.49,;4,4.72,;4,3.18,;2.67,2.41,;2.67,.87,;1.33,.1,;4,.1,;5.33,.87,;6.67,.1,;5.33,2.41,;4,-1.44,;2.67,-2.21,;2.67,-3.75,;4,-4.52,;5.33,-3.75,;5.33,-2.21,;6.67,-1.44,;1.33,-4.52,;1.33,-6.06,;,-3.75,;-1.33,-4.52,;-1.33,-6.06,;-2.67,-6.83,;-4,-6.06,;-4,-4.52,;-2.67,-3.75,;-2.67,-2.21,;-1.33,-1.44,;-1.33,.1,;,.87,;-2.67,.87,;-2.67,2.41,;-4,3.18,;-4,4.72,;-5.33,5.49,;-6.1,4.16,;-6.67,6.26,;-4.56,6.83,;-4,.1,;-5.33,.87,;-4,-1.44,)|
Show InChI InChI=1S/C28H31F3N4O5S/c1-15-10-16(11-22(32)27(15)40-8-9-41(3,37)38)18-6-7-33-14-24(18)35-28(36)23-5-4-19(29)26(34-23)25-20(30)12-17(39-2)13-21(25)31/h4-7,12-16,22,27H,8-11,32H2,1-3H3,(H,35,36)/t15-,16+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151952
PNG
(US8987457, 146)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1OCCS(C)(=O)=O)c1ccncc1NC(=O)c1nc(c(F)cc1N)-c1c(F)cccc1F |r,wU:3.15,1.0,5.5,7.8,(,.87,;-1.33,.1,;-1.33,-1.44,;-2.67,-2.21,;-4,-1.44,;-4,.1,;-5.33,.87,;-2.67,.87,;-2.67,2.41,;-4,3.18,;-4,4.72,;-5.33,5.49,;-6.1,4.16,;-6.67,6.26,;-4.56,6.83,;-2.67,-3.75,;-4,-4.52,;-4,-6.06,;-2.67,-6.83,;-1.33,-6.06,;-1.33,-4.52,;,-3.75,;1.33,-4.52,;1.33,-6.06,;2.67,-3.75,;2.67,-2.21,;4,-1.44,;5.33,-2.21,;6.67,-1.44,;5.33,-3.75,;4,-4.52,;4,-6.06,;4,.1,;2.67,.87,;1.33,.1,;2.67,2.41,;4,3.18,;5.33,2.41,;5.33,.87,;6.67,.1,)|
Show InChI InChI=1S/C27H30F3N5O4S/c1-14-10-15(11-21(32)26(14)39-8-9-40(2,37)38)16-6-7-33-13-22(16)34-27(36)25-20(31)12-19(30)24(35-25)23-17(28)4-3-5-18(23)29/h3-7,12-15,21,26H,8-11,31-32H2,1-2H3,(H,34,36)/t14-,15+,21+,26-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151954
PNG
(US8987457, 148)
Show SMILES COC(=O)N[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC(C)C)cc1F |r,wU:6.6,11.12,5.4,(.67,3.08,;-.67,2.31,;-2,3.08,;-2,4.62,;-3.33,2.31,;-3.33,.77,;-2,,;-.67,.77,;-2,-1.54,;-3.33,-2.31,;-4.67,-1.54,;-4.67,,;-6,.77,;-3.33,-3.85,;-4.67,-4.62,;-4.67,-6.16,;-3.33,-6.93,;-2,-6.16,;-2,-4.62,;-.67,-3.85,;.67,-4.62,;.67,-6.16,;2,-3.85,;3.33,-4.62,;4.67,-3.85,;4.67,-2.31,;6,-1.54,;3.33,-1.54,;2,-2.31,;3.33,,;2,.77,;.67,,;2,2.31,;3.33,3.08,;3.33,4.62,;4.67,5.39,;4.67,6.93,;6,4.62,;4.67,2.31,;4.67,.77,;6,,)|
Show InChI InChI=1S/C28H31F3N6O4/c1-14(2)41-16-9-18(30)24(19(31)10-16)26-17(29)5-6-21(34-26)27(38)35-22-11-33-8-7-23(22)37-12-15(3)25(20(32)13-37)36-28(39)40-4/h5-11,14-15,20,25H,12-13,32H2,1-4H3,(H,35,38)(H,36,39)/t15-,20+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151965
PNG
(US8987457, 159)
Show SMILES COC(=O)N[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(OC2CCOCC2)cc1F |r,wU:6.6,11.12,5.4,(-7.17,3.7,;-6.08,2.62,;-4.59,3.01,;-4.19,4.5,;-3.5,1.93,;-3.5,.38,;-2.17,-.38,;-.83,.38,;-2.17,-1.93,;-3.5,-2.69,;-4.84,-1.93,;-4.84,-.38,;-6.17,.38,;-3.5,-4.23,;-4.84,-5,;-4.84,-6.54,;-3.5,-7.31,;-2.17,-6.54,;-2.17,-5,;-.83,-4.23,;.5,-5,;.5,-6.54,;1.83,-4.23,;3.17,-5,;4.5,-4.23,;4.5,-2.69,;5.83,-1.92,;3.17,-1.93,;1.83,-2.69,;3.17,-.38,;1.83,.38,;.5,-.38,;1.83,1.93,;3.17,2.69,;3.17,4.23,;4.5,5,;5.83,4.24,;7.17,5,;7.17,6.54,;5.83,7.31,;4.5,6.54,;4.5,1.93,;4.5,.38,;5.83,-.38,)|
Show InChI InChI=1S/C30H33F3N6O5/c1-16-14-39(15-22(34)27(16)38-30(41)42-2)25-5-8-35-13-24(25)37-29(40)23-4-3-19(31)28(36-23)26-20(32)11-18(12-21(26)33)44-17-6-9-43-10-7-17/h3-5,8,11-13,16-17,22,27H,6-7,9-10,14-15,34H2,1-2H3,(H,37,40)(H,38,41)/t16-,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151967
PNG
(US8987457, 161)
Show SMILES C[C@H]1CN(C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:1.0,5.5,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;3.33,-3.49,;4.67,-2.72,;4.67,-1.18,;6,-.41,;3.33,-.41,;2,-1.18,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;3.33,5.75,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C26H25F3N8O/c1-14-9-17(28)23(18(29)10-14)24-16(27)3-4-20(33-24)26(38)34-21-11-31-6-5-22(21)36-12-15(2)25(19(30)13-36)37-8-7-32-35-37/h3-11,15,19,25H,12-13,30H2,1-2H3,(H,34,38)/t15-,19+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151971
PNG
(US8987457, 165)
Show SMILES COc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1[C@@H]1C[C@H](C)[C@H](OCCC#N)[C@H](N)C1 |r,wU:26.28,28.31,36.39,30.33,(4.67,5.78,;3.33,5,;3.33,3.47,;2,2.69,;2,1.15,;.67,.38,;3.33,.38,;4.67,1.15,;6,.38,;4.67,2.69,;3.33,-1.15,;2,-1.93,;2,-3.47,;3.33,-4.23,;4.67,-3.47,;4.67,-1.93,;6,-1.15,;.67,-4.23,;.67,-5.78,;-.67,-3.47,;-2,-4.23,;-2,-5.78,;-3.33,-6.54,;-4.67,-5.78,;-4.67,-4.23,;-3.33,-3.47,;-3.33,-1.93,;-2,-1.15,;-2,.38,;-.67,1.15,;-3.33,1.15,;-3.33,2.69,;-2,3.47,;-2,5,;-.67,5.78,;.67,6.54,;-4.67,.38,;-6,1.15,;-4.67,-1.15,)|
Show InChI InChI=1S/C28H28F3N5O3/c1-15-10-16(11-22(33)27(15)39-9-3-7-32)18-6-8-34-14-24(18)36-28(37)23-5-4-19(29)26(35-23)25-20(30)12-17(38-2)13-21(25)31/h4-6,8,12-16,22,27H,3,9-11,33H2,1-2H3,(H,36,37)/t15-,16+,22+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151839
PNG
(US8987457, 33)
Show SMILES CS[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:6.10,3.3,8.9,2.1,(-2,5.01,;-3.33,4.23,;-3.33,2.69,;-2,1.93,;-.67,2.69,;-2,.38,;-3.33,-.39,;-4.67,.38,;-4.67,1.93,;-6,2.69,;-3.33,-1.93,;-4.67,-2.7,;-4.67,-4.24,;-3.33,-5.01,;-2,-4.24,;-2,-2.7,;-.67,-1.93,;.67,-2.7,;.67,-4.24,;2,-1.93,;3.33,-2.7,;4.67,-1.93,;4.67,-.39,;6,.38,;3.33,.38,;2,-.39,;3.33,1.92,;2,2.69,;.67,1.93,;2,4.23,;3.33,5,;4.67,4.23,;4.67,2.69,;6,1.93,)|
Show InChI InChI=1S/C25H25F3N4OS/c1-13-10-14(11-19(29)24(13)34-2)15-8-9-30-12-21(15)32-25(33)20-7-6-18(28)23(31-20)22-16(26)4-3-5-17(22)27/h3-9,12-14,19,24H,10-11,29H2,1-2H3,(H,32,33)/t13-,14+,19+,24-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151862
PNG
(US8987457, 56)
Show SMILES C[C@H]1CN(C[C@@H](N)[C@H]1n1cncn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:5.5,1.0,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;3.33,-3.49,;4.67,-2.72,;4.67,-1.18,;6,-.41,;3.33,-.41,;2,-1.18,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C25H23F3N8O/c1-14-10-35(11-18(29)24(14)36-13-31-12-32-36)21-7-8-30-9-20(21)34-25(37)19-6-5-17(28)23(33-19)22-15(26)3-2-4-16(22)27/h2-9,12-14,18,24H,10-11,29H2,1H3,(H,34,37)/t14-,18+,24-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151864
PNG
(US8987457, 58)
Show SMILES COC(=O)N(C)[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:12.13,7.7,6.5,(.67,4.24,;-.67,3.47,;-2,4.24,;-2,5.78,;-3.33,3.46,;-4.67,4.23,;-3.33,1.92,;-2,1.16,;-.67,1.93,;-2,-.38,;-3.33,-1.16,;-4.67,-.38,;-4.67,1.16,;-6,1.93,;-3.33,-2.7,;-4.67,-3.47,;-4.67,-5.01,;-3.33,-5.78,;-2,-5.01,;-2,-3.47,;-.67,-2.7,;.67,-3.47,;.67,-5.01,;2,-2.7,;3.33,-3.46,;4.67,-2.7,;4.67,-1.16,;6,-.38,;3.33,-.39,;2,-1.16,;3.33,1.15,;2,1.92,;.67,1.15,;2,3.46,;3.33,4.23,;3.33,5.77,;4.67,3.46,;4.67,1.92,;6,1.15,)|
Show InChI InChI=1S/C27H29F3N6O3/c1-14-9-17(29)23(18(30)10-14)24-16(28)5-6-20(33-24)26(37)34-21-11-32-8-7-22(21)36-12-15(2)25(19(31)13-36)35(3)27(38)39-4/h5-11,15,19,25H,12-13,31H2,1-4H3,(H,34,37)/t15-,19+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase B-raf [V600E]


(Homo sapiens (Human))
BDBM87369
PNG
(US10245267, Example 704 | US10709712, Example 704 ...)
Show SMILES CCNc1nc(cc(n1)-c1cc(NC(=O)c2cccc(c2)S(C)(=O)=O)ccc1C)N1CCOCC1
Show InChI InChI=1S/C25H29N5O4S/c1-4-26-25-28-22(16-23(29-25)30-10-12-34-13-11-30)21-15-19(9-8-17(21)2)27-24(31)18-6-5-7-20(14-18)35(3,32)33/h5-9,14-16H,4,10-13H2,1-3H3,(H,27,31)(H,26,28,29)
PDB

UniProtKB/SwissProt

GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0200n/an/an/an/an/an/a



Bristol-Myers Squibb Company



Assay Description
Raf and biotinylated Mek, kinase dead, were combined at 2× final concentrations in assay buffer (50 mM Tris, pH 7.5, 15 mM MgCl2, 0.01% BSA and 1 mM ...


Bioorg Med Chem Lett 17: 5115-20 (2007)


BindingDB Entry DOI: 10.7270/Q2RB76WP
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151953
PNG
(US8987457, 147)
Show SMILES CC(C)Oc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1N1C[C@H](C)[C@@H]([C@H](N)C1)n1ccnn1 |r,wU:30.33,33.36,32.39,(4.02,7.06,;4.42,5.58,;5.91,5.18,;3.33,4.49,;3.33,2.95,;2,2.18,;2,.64,;.67,-.13,;3.33,-.13,;4.67,.64,;6,-.13,;4.67,2.18,;3.33,-1.67,;2,-2.44,;2,-3.98,;3.33,-4.75,;4.67,-3.98,;4.67,-2.44,;6,-1.67,;.67,-4.75,;.67,-6.29,;-.67,-3.98,;-2,-4.75,;-2,-6.29,;-3.33,-7.06,;-4.67,-6.29,;-4.67,-4.75,;-3.33,-3.98,;-3.33,-2.44,;-2,-1.67,;-2,-.13,;-.67,.64,;-3.33,.64,;-4.67,-.13,;-6,.64,;-4.67,-1.67,;-3.33,2.18,;-4.58,3.08,;-4.1,4.55,;-2.56,4.55,;-2.09,3.08,)|
Show InChI InChI=1S/C28H29F3N8O2/c1-15(2)41-17-10-19(30)25(20(31)11-17)26-18(29)4-5-22(35-26)28(40)36-23-12-33-7-6-24(23)38-13-16(3)27(21(32)14-38)39-9-8-34-37-39/h4-12,15-16,21,27H,13-14,32H2,1-3H3,(H,36,40)/t16-,21+,27-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151893
PNG
(US8987457, 87)
Show SMILES C[C@H]1CN(C[C@@H](N)[C@H]1N=[N+]=[N-])c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:5.5,1.0,7.8,(-.67,2.31,;-2,1.54,;-2,,;-3.33,-.77,;-4.67,,;-4.67,1.54,;-6,2.31,;-3.33,2.31,;-3.33,3.85,;-2,4.62,;-.67,5.39,;-3.33,-2.31,;-4.67,-3.08,;-4.67,-4.62,;-3.33,-5.39,;-2,-4.62,;-2,-3.08,;-.67,-2.31,;.67,-3.08,;.67,-4.62,;2,-2.31,;3.33,-3.08,;4.67,-2.31,;4.67,-.77,;6,,;3.33,,;2,-.77,;3.33,1.54,;2,2.31,;.67,1.54,;2,3.85,;3.33,4.62,;4.67,3.85,;4.67,2.31,;6,1.54,)|
Show InChI InChI=1S/C23H21F3N8O/c1-12-10-34(11-16(27)21(12)32-33-28)19-7-8-29-9-18(19)31-23(35)17-6-5-15(26)22(30-17)20-13(24)3-2-4-14(20)25/h2-9,12,16,21H,10-11,27H2,1H3,(H,31,35)/t12-,16+,21-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151985
PNG
(US8987457, 179)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCOCC1 |r,wU:3.14,1.0,5.5,7.8,(-.67,.38,;-2,-.38,;-2,-1.93,;-3.33,-2.69,;-4.67,-1.93,;-4.67,-.38,;-6,.38,;-3.33,.38,;-3.33,1.93,;-4.58,2.83,;-4.1,4.29,;-2.56,4.29,;-2.09,2.83,;-3.33,-4.23,;-4.67,-5,;-4.67,-6.54,;-3.33,-7.31,;-2,-6.54,;-2,-5,;-.67,-4.23,;.67,-5,;.67,-6.54,;2,-4.23,;3.33,-5,;4.67,-4.23,;4.67,-2.69,;6,-1.92,;3.33,-1.93,;2,-2.69,;3.33,-.38,;2,.38,;.67,-.38,;2,1.93,;3.33,2.69,;4.67,1.93,;4.67,.38,;6,-.38,;3.33,4.23,;4.67,3.47,;4.67,5,;4.67,6.54,;3.33,7.31,;2,6.54,;2,5,)|
Show InChI InChI=1S/C31H32F3N7O3/c1-17-12-18(13-24(35)29(17)41-9-8-37-40-41)20-4-7-36-16-26(20)39-30(42)25-3-2-21(32)28(38-25)27-22(33)14-19(15-23(27)34)31(43)5-10-44-11-6-31/h2-4,7-9,14-18,24,29,43H,5-6,10-13,35H2,1H3,(H,39,42)/t17-,18+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151987
PNG
(US8987457, 181)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:3.14,1.0,5.5,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;3.33,-3.49,;4.67,-2.72,;4.67,-1.18,;6,-.41,;3.33,-.41,;2,-1.18,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;3.33,5.75,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C27H26F3N7O/c1-14-9-19(29)24(20(30)10-14)25-18(28)3-4-22(34-25)27(38)35-23-13-32-6-5-17(23)16-11-15(2)26(21(31)12-16)37-8-7-33-36-37/h3-10,13,15-16,21,26H,11-12,31H2,1-2H3,(H,35,38)/t15-,16+,21+,26-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151999
PNG
(US8987457, 193)
Show SMILES COc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1N1C[C@H](C)[C@@H]([C@H](N)C1)n1ccnn1 |r,wU:28.31,31.34,30.37,(4.67,6.16,;3.33,5.39,;3.33,3.85,;2,3.08,;2,1.54,;.67,.77,;3.33,.77,;4.67,1.54,;6,.77,;4.67,3.08,;3.33,-.77,;2,-1.54,;2,-3.08,;3.33,-3.85,;4.67,-3.08,;4.67,-1.54,;6,-.77,;.67,-3.85,;.67,-5.39,;-.67,-3.08,;-2,-3.85,;-2,-5.39,;-3.33,-6.16,;-4.67,-5.39,;-4.67,-3.85,;-3.33,-3.08,;-3.33,-1.54,;-2,-.77,;-2,.77,;-.67,1.54,;-3.33,1.54,;-4.67,.77,;-6,1.54,;-4.67,-.77,;-3.33,3.08,;-4.58,3.99,;-4.1,5.45,;-2.56,5.45,;-2.09,3.99,)|
Show InChI InChI=1S/C26H25F3N8O2/c1-14-12-36(13-19(30)25(14)37-8-7-32-35-37)22-5-6-31-11-21(22)34-26(38)20-4-3-16(27)24(33-20)23-17(28)9-15(39-2)10-18(23)29/h3-11,14,19,25H,12-13,30H2,1-2H3,(H,34,38)/t14-,19+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151900
PNG
(US8987457, 94)
Show SMILES CO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1CCS(=O)(=O)CC1 |r,wU:6.10,8.9,3.3,2.1,(-2,2.03,;-3.33,1.26,;-3.33,-.28,;-2,-1.05,;-.67,-.28,;-2,-2.59,;-3.33,-3.36,;-4.67,-2.59,;-4.67,-1.05,;-6,-.28,;-3.33,-4.9,;-4.67,-5.67,;-4.67,-7.21,;-3.33,-7.98,;-2,-7.21,;-2,-5.67,;-.67,-4.9,;.67,-5.67,;.67,-7.21,;2,-4.9,;3.33,-5.67,;4.67,-4.9,;4.67,-3.36,;6,-2.59,;3.33,-2.59,;2,-3.36,;3.33,-1.05,;2,-.28,;.67,-1.05,;2,1.26,;3.33,2.03,;4.67,1.26,;4.67,-.28,;6,-1.05,;3.33,3.57,;4.67,4.34,;4.67,5.88,;3.33,6.65,;2.56,7.98,;4.1,7.98,;2,5.88,;2,4.34,)|
Show InChI InChI=1S/C30H33F3N4O4S/c1-16-11-19(14-24(34)29(16)41-2)20-5-8-35-15-26(20)37-30(38)25-4-3-21(31)28(36-25)27-22(32)12-18(13-23(27)33)17-6-9-42(39,40)10-7-17/h3-5,8,12-13,15-17,19,24,29H,6-7,9-11,14,34H2,1-2H3,(H,37,38)/t16-,19+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151908
PNG
(US8987457, 102)
Show SMILES CO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:6.10,8.9,3.3,2.1,(-2,4.23,;-3.33,3.47,;-3.33,1.93,;-2,1.16,;-.67,1.93,;-2,-.38,;-3.33,-1.15,;-4.67,-.38,;-4.67,1.16,;-6,1.93,;-3.33,-2.69,;-4.67,-3.47,;-4.67,-5,;-3.33,-5.78,;-2,-5,;-2,-3.47,;-.67,-2.69,;.67,-3.47,;.67,-5,;2,-2.69,;3.33,-3.46,;4.67,-2.69,;4.67,-1.15,;6,-.38,;3.33,-.38,;2,-1.15,;3.33,1.15,;2,1.93,;.67,1.15,;2,3.47,;3.33,4.23,;3.33,5.78,;4.67,3.47,;4.67,1.93,;6,1.15,)|
Show InChI InChI=1S/C26H27F3N4O2/c1-13-8-18(28)23(19(29)9-13)24-17(27)4-5-21(32-24)26(34)33-22-12-31-7-6-16(22)15-10-14(2)25(35-3)20(30)11-15/h4-9,12,14-15,20,25H,10-11,30H2,1-3H3,(H,33,34)/t14-,15+,20+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151923
PNG
(US8987457, 117)
Show SMILES CO[C@@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCOCC1 |r,wU:6.10,8.9,3.3,wD:2.1,(-2,2.69,;-3.33,1.93,;-3.33,.38,;-2,-.38,;-.67,.39,;-2,-1.92,;-3.33,-2.69,;-4.67,-1.92,;-4.67,-.38,;-6,.39,;-3.33,-4.23,;-4.67,-5,;-4.67,-6.54,;-3.33,-7.31,;-2,-6.54,;-2,-5,;-.67,-4.23,;.67,-5,;.67,-6.54,;2,-4.23,;3.33,-5,;4.67,-4.23,;4.67,-2.69,;6,-1.92,;3.33,-1.93,;2,-2.69,;3.33,-.38,;2,.38,;.67,-.38,;2,1.93,;3.33,2.69,;4.67,1.93,;4.67,.38,;6,-.38,;3.33,4.23,;4.67,3.47,;4.67,5,;4.67,6.54,;3.33,7.31,;2,6.54,;2,5,)|
Show InChI InChI=1S/C30H33F3N4O4/c1-16-11-17(12-23(34)28(16)40-2)19-5-8-35-15-25(19)37-29(38)24-4-3-20(31)27(36-24)26-21(32)13-18(14-22(26)33)30(39)6-9-41-10-7-30/h3-5,8,13-17,23,28,39H,6-7,9-12,34H2,1-2H3,(H,37,38)/t16-,17+,23+,28+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151929
PNG
(US8987457, 123)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1Oc1ccccn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:3.16,5.5,1.0,7.8,(-.67,1.54,;-2,.77,;-2,-.77,;-3.33,-1.54,;-4.67,-.77,;-4.67,.77,;-6,1.54,;-3.33,1.54,;-3.33,3.08,;-2,3.85,;-.67,3.08,;.67,3.85,;.67,5.39,;-.67,6.16,;-2,5.39,;-3.33,-3.08,;-4.67,-3.85,;-4.67,-5.39,;-3.33,-6.16,;-2,-5.39,;-2,-3.85,;-.67,-3.08,;.67,-3.85,;.67,-5.39,;2,-3.08,;3.33,-3.85,;4.67,-3.08,;4.67,-1.54,;6,-.77,;3.33,-.77,;2,-1.54,;3.33,.77,;2,1.54,;.67,.77,;2,3.08,;3.33,3.85,;4.67,3.08,;4.67,1.54,;6,.77,)|
Show InChI InChI=1S/C29H26F3N5O2/c1-16-13-17(14-22(33)28(16)39-25-7-2-3-11-35-25)18-10-12-34-15-24(18)37-29(38)23-9-8-21(32)27(36-23)26-19(30)5-4-6-20(26)31/h2-12,15-17,22,28H,13-14,33H2,1H3,(H,37,38)/t16-,17+,22+,28-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151936
PNG
(US8987457, 130)
Show SMILES COCCOc1cc(F)c(c(F)c1)-c1nc(ccc1F)C(=O)Nc1cnccc1[C@@H]1C[C@H](C)[C@H](OCCS(C)(=O)=O)[C@H](N)C1 |r,wU:29.31,31.34,41.44,33.36,(8,4.62,;6.67,5.39,;5.33,4.62,;4,5.39,;2.67,4.62,;2.67,3.08,;1.33,2.31,;1.33,.77,;;2.67,,;4,.77,;5.33,,;4,2.31,;2.67,-1.54,;1.33,-2.31,;1.33,-3.85,;2.67,-4.62,;4,-3.85,;4,-2.31,;5.33,-1.54,;,-4.62,;,-6.16,;-1.33,-3.85,;-2.67,-4.62,;-2.67,-6.16,;-4,-6.93,;-5.33,-6.16,;-5.33,-4.62,;-4,-3.85,;-4,-2.31,;-2.67,-1.54,;-2.67,,;-1.33,.77,;-4,.77,;-4,2.31,;-5.33,3.08,;-5.33,4.62,;-6.67,5.39,;-6.67,6.93,;-7.44,4.06,;-8,6.16,;-5.33,,;-6.67,.77,;-5.33,-1.54,)|
Show InChI InChI=1S/C30H35F3N4O6S/c1-17-12-18(13-24(34)29(17)43-10-11-44(3,39)40)20-6-7-35-16-26(20)37-30(38)25-5-4-21(31)28(36-25)27-22(32)14-19(15-23(27)33)42-9-8-41-2/h4-7,14-18,24,29H,8-13,34H2,1-3H3,(H,37,38)/t17-,18+,24+,29-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151944
PNG
(US8987457, 138)
Show SMILES CO[C@@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(cc1F)C1(O)CCC1 |r,wU:6.10,3.3,8.9,wD:2.1,(-4.67,3.15,;-3.33,2.38,;-3.33,.84,;-2,.07,;-.67,.84,;-2,-1.47,;-3.33,-2.24,;-4.67,-1.47,;-4.67,.07,;-6,.84,;-3.33,-3.78,;-4.67,-4.55,;-4.67,-6.09,;-3.33,-6.86,;-2,-6.09,;-2,-4.55,;-.67,-3.78,;.67,-4.55,;.67,-6.09,;2,-3.78,;3.33,-4.55,;4.67,-3.78,;4.67,-2.24,;6,-1.47,;3.33,-1.47,;2,-2.24,;3.33,.07,;2,.84,;.67,.07,;2,2.38,;3.33,3.15,;4.67,2.38,;4.67,.84,;6,.07,;3.33,4.69,;4.67,3.92,;4.42,5.78,;3.33,6.86,;2.25,5.78,)|
Show InChI InChI=1S/C29H31F3N4O3/c1-15-10-16(11-22(33)27(15)39-2)18-6-9-34-14-24(18)36-28(37)23-5-4-19(30)26(35-23)25-20(31)12-17(13-21(25)32)29(38)7-3-8-29/h4-6,9,12-16,22,27,38H,3,7-8,10-11,33H2,1-2H3,(H,36,37)/t15-,16+,22+,27+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151894
PNG
(US8987457, 88)
Show SMILES CCO[C@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:7.11,9.10,4.4,3.2,(-4.67,5.78,;-4.67,4.24,;-3.33,3.46,;-3.33,1.92,;-2,1.16,;-.67,1.93,;-2,-.38,;-3.33,-1.16,;-4.67,-.38,;-4.67,1.16,;-6,1.93,;-3.33,-2.7,;-4.67,-3.47,;-4.67,-5.01,;-3.33,-5.78,;-2,-5.01,;-2,-3.47,;-.67,-2.7,;.67,-3.47,;.67,-5.01,;2,-2.7,;3.33,-3.46,;4.67,-2.7,;4.67,-1.16,;6,-.38,;3.33,-.39,;2,-1.16,;3.33,1.15,;2,1.92,;.67,1.15,;2,3.46,;3.33,4.23,;4.67,3.46,;4.67,1.92,;6,1.15,)|
Show InChI InChI=1S/C26H27F3N4O2/c1-3-35-25-14(2)11-15(12-20(25)30)16-9-10-31-13-22(16)33-26(34)21-8-7-19(29)24(32-21)23-17(27)5-4-6-18(23)28/h4-10,13-15,20,25H,3,11-12,30H2,1-2H3,(H,33,34)/t14-,15+,20+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151811
PNG
(US8987457, 5)
Show SMILES C[C@H]1CN(C[C@@H](N)[C@H]1n1ccnn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:1.0,5.5,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;3.33,-3.49,;4.67,-2.72,;4.67,-1.18,;6,-.41,;3.33,-.41,;2,-1.18,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C25H23F3N8O/c1-14-12-35(13-18(29)24(14)36-10-9-31-34-36)21-7-8-30-11-20(21)33-25(37)19-6-5-17(28)23(32-19)22-15(26)3-2-4-16(22)27/h2-11,14,18,24H,12-13,29H2,1H3,(H,33,37)/t14-,18+,24-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151855
PNG
(US8987457, 49)
Show SMILES C[C@H]1C[C@H](C[C@@H](N)[C@H]1n1cncn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:3.14,1.0,5.5,7.8,(-.67,1.9,;-2,1.13,;-2,-.41,;-3.33,-1.18,;-4.67,-.41,;-4.67,1.13,;-6,1.9,;-3.33,1.9,;-3.33,3.44,;-4.58,4.34,;-4.1,5.8,;-2.56,5.8,;-2.09,4.34,;-3.33,-2.72,;-4.67,-3.49,;-4.67,-5.03,;-3.33,-5.8,;-2,-5.03,;-2,-3.49,;-.67,-2.72,;.67,-3.49,;.67,-5.03,;2,-2.72,;3.33,-3.49,;4.67,-2.72,;4.67,-1.18,;6,-.41,;3.33,-.41,;2,-1.18,;3.33,1.13,;2,1.9,;.67,1.13,;2,3.44,;3.33,4.21,;4.67,3.44,;4.67,1.9,;6,1.13,)|
Show InChI InChI=1S/C26H24F3N7O/c1-14-9-15(10-20(30)25(14)36-13-32-12-33-36)16-7-8-31-11-22(16)35-26(37)21-6-5-19(29)24(34-21)23-17(27)3-2-4-18(23)28/h2-8,11-15,20,25H,9-10,30H2,1H3,(H,35,37)/t14-,15+,20+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151867
PNG
(US8987457, 61)
Show SMILES COC(=O)N(C)[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:12.13,7.7,6.5,(-6.67,4.23,;-5.33,3.47,;-4,4.23,;-4,5.78,;-2.67,3.47,;-1.33,4.24,;-2.67,1.93,;-1.33,1.16,;,1.93,;-1.33,-.38,;-2.67,-1.15,;-4,-.38,;-4,1.16,;-5.33,1.93,;-2.67,-2.69,;-4,-3.47,;-4,-5,;-2.67,-5.78,;-1.33,-5,;-1.33,-3.47,;,-2.69,;1.33,-3.47,;1.33,-5,;2.67,-2.69,;4,-3.46,;5.33,-2.69,;5.33,-1.15,;6.67,-.38,;4,-.38,;2.67,-1.15,;4,1.15,;2.67,1.93,;1.33,1.15,;2.67,3.47,;4,4.23,;5.33,3.47,;5.33,1.93,;6.67,1.15,)|
Show InChI InChI=1S/C26H27F3N6O3/c1-14-12-35(13-18(30)24(14)34(2)26(37)38-3)21-9-10-31-11-20(21)33-25(36)19-8-7-17(29)23(32-19)22-15(27)5-4-6-16(22)28/h4-11,14,18,24H,12-13,30H2,1-3H3,(H,33,36)/t14-,18+,24-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151868
PNG
(US8987457, 62)
Show SMILES CO[C@@H]1[C@@H](C)C[C@H](C[C@H]1N)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cc(C)cc1F |r,wU:6.10,8.9,3.3,wD:2.1,(-2,4.24,;-3.33,3.47,;-3.33,1.93,;-2,1.16,;-.67,1.93,;-2,-.38,;-3.33,-1.15,;-4.67,-.38,;-4.67,1.16,;-6,1.93,;-3.33,-2.69,;-4.67,-3.47,;-4.67,-5,;-3.33,-5.78,;-2,-5,;-2,-3.47,;-.67,-2.69,;.67,-3.47,;.67,-5,;2,-2.69,;3.33,-3.46,;4.67,-2.69,;4.67,-1.15,;6,-.38,;3.33,-.38,;2,-1.15,;3.33,1.15,;2,1.93,;.67,1.15,;2,3.47,;3.33,4.23,;3.33,5.78,;4.67,3.47,;4.67,1.93,;6,1.15,)|
Show InChI InChI=1S/C26H27F3N4O2/c1-13-8-18(28)23(19(29)9-13)24-17(27)4-5-21(32-24)26(34)33-22-12-31-7-6-16(22)15-10-14(2)25(35-3)20(30)11-15/h4-9,12,14-15,20,25H,10-11,30H2,1-3H3,(H,33,34)/t14-,15+,20+,25+/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151872
PNG
(US8987457, 66)
Show SMILES C[C@H]1CN(C[C@@H](N)[C@H]1n1cc(CO)nn1)c1ccncc1NC(=O)c1ccc(F)c(n1)-c1c(F)cccc1F |r,wU:5.5,1.0,7.8,(-.67,.56,;-2,-.21,;-2,-1.75,;-3.33,-2.52,;-4.67,-1.75,;-4.67,-.21,;-6,.56,;-3.33,.56,;-3.33,2.1,;-2.09,3.01,;-2.56,4.47,;-1.79,5.8,;-2.56,7.14,;-4.1,4.47,;-4.58,3.01,;-3.33,-4.06,;-4.67,-4.83,;-4.67,-6.37,;-3.33,-7.14,;-2,-6.37,;-2,-4.83,;-.67,-4.06,;.67,-4.83,;.67,-6.37,;2,-4.06,;3.33,-4.83,;4.67,-4.06,;4.67,-2.52,;6,-1.75,;3.33,-1.75,;2,-2.52,;3.33,-.21,;2,.56,;.67,-.21,;2,2.1,;3.33,2.87,;4.67,2.1,;4.67,.56,;6,-.21,)|
Show InChI InChI=1S/C26H25F3N8O2/c1-14-10-36(12-19(30)25(14)37-11-15(13-38)34-35-37)22-7-8-31-9-21(22)33-26(39)20-6-5-18(29)24(32-20)23-16(27)3-2-4-17(23)28/h2-9,11,14,19,25,38H,10,12-13,30H2,1H3,(H,33,39)/t14-,19+,25-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Serine/threonine-protein kinase pim-1


(Homo sapiens (Human))
BDBM151878
PNG
(US8987457, 72)
Show SMILES COC(=O)N[C@H]1[C@@H](C)CN(C[C@H]1N)c1ccncc1NC(=O)c1nc(sc1N)-c1c(F)cccc1F |r|
Show InChI InChI=1S/C23H25F2N7O3S/c1-11-9-32(10-14(26)18(11)31-23(34)35-2)16-6-7-28-8-15(16)29-21(33)19-20(27)36-22(30-19)17-12(24)4-3-5-13(17)25/h3-8,11,14,18H,9-10,26-27H2,1-2H3,(H,29,33)(H,31,34)/t11-,14+,18-/m0/s1
PDB
MMDB

KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem

Similars

US Patent
n/an/a 0.0300n/an/an/an/an/an/a



Novartis AG

US Patent


Assay Description
Pim 1, Pim 2 & Pim 3 AlphaScreen assays using high ATP (11-125.times. ATP Km) were used to determine the biochemical activity of the inhibitors. The ...


US Patent US8987457 (2015)


BindingDB Entry DOI: 10.7270/Q2765D2M
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 9387 total )  |  Next  |  Last  >>
Jump to: